Clinical trials: Wet AMD
Wet Age-related Macular Degeneration (wAMD)
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD.
- Trial name
- NCT06718816
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.
Maculopathy, Maculopathy, Age Related
CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking
The development of a next-generation 'CRYSTALSIGHT' solution using combinations of a novel and cost-effective eye-tracking system with artificial intelligence-based eye-tracking algorithms that detect macular abnormalities and…
- Conditions
- Maculopathy, Maculopathy, Age Related, Macular Degeneration, Age-Related, Diabetic Retinopathy
- Trial name
- NCT07255885
- Testing
- CRYSTALSIGHT Test
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Tan Tock Seng Hospital
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to the contralateral (second) eye of adult participants (≥ 50 years of…
- Trial name
- NCT07630649
- Testing
- Ixo-vec
- Where
- 12 sites in United States
- Volunteers
- 15 people
- Sponsor
- Adverum Biotechnologies, Inc.
Age-Related Macular Degeneration
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis®…
- Trial name
- NCT03211234
- Testing
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Where
- 14 sites in United States, Philippines
- Volunteers
- 76 people
- Sponsor
- Santen Inc.
Macular Degeneration, Age-related Macular Degeneration
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
Long-term observational study to assess the safety, efficacy and quality of life of patients with neovascular age-related macular degeneration (AMD) under Macugen treatment.
- Conditions
- Macular Degeneration, Age-related Macular Degeneration, Neovascular Macular Degeneration
- Trial name
- MACULA (NCT01245387)
- Testing
- Pegaptanib
- Volunteers
- 1,001 people
- Sponsor
- Pfizer
Age-Related Macular Degeneration (AMD), Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab
Age-related macular degeneration (AMD) is a common eye disease that can lead to vision loss. The neovascular ("wet") form of AMD is usually treated with repeated injections into the eye.
- Trial name
- NCT07744984
- Testing
- Home Optical Coherence Tomography (Home OCT)
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Rabin Medical Center
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion
Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy
This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO)…
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07501052
- Testing
- SCD411 0.05mL (2mg)
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye.
- Trial name
- NCT05989126
- Testing
- aflibercept 8 mg PFS
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
Wet Age-related Macular Degeneration
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
The purpose of this study is to compare the efficacy and safety of SCT510A versus Lucentis in the treatment of wet age-related macular degeneration.
- Trial name
- NCT05480293
- Testing
- Ranibizumab, SCT510A
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Sinocelltech Ltd.
Age-Related Macular Degeneration, Wet Age-related Macular Degeneration
User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems
Age-Related Macular Degeneration (AMD) is the leading cause of central vision loss among older adults worldwide. Patients with AMD often require frequent monitoring of visual function and disease progression, typically through…
- Trial name
- AVIGA-SURVEY (NCT07338513)
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Tan Tock Seng Hospital
Neovascular (Wet) Age-Related Macular Degeneration
Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration
The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile.
- Trial name
- NCT07557121
- Testing
- AIV007, EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Volunteers
- 35 people
- Sponsor
- AiViva BioPharma, Inc.
Age Related Macular Degeneration
A Study of Implantation of Retinal Pigment Epithelium in Subjects with Acute Wet Age Related Macular Degeneration
Phase 1 trial of retinal pigment epithelium replacement in subjects with wet age-related macular degeneration in whom there is rapidly progressing vision loss
- Trial name
- NCT01691261
- Testing
- PF-05206388
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Age-Related Macular Degeneration
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent…
- Trial name
- NCT02357342
- Testing
- Sirolimus, Standard of Care intravitreal injections of anti-VEGF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Macular Degeneration
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and December 31…
- Trial name
- REVIEW (NCT01933152)
- Testing
- Ranibizumab
- Where
- Portugal
- Volunteers
- 137 people
- Sponsor
- Bayer
Wet Age Related Macular Degeneration, Neovascular (Wet) Age-Related Macular Degeneration
Evaluation of PAN-90806 Eye Drops in Healthy Subjects
The goal of this clinical trial is to learn about the safety, tolerability, and systemic pharmacokinetics of PAN-90806 eye drops in healthy adults.
- Trial name
- NCT07764965
- Testing
- PAN-90806 Ophthalmic Solution, Vehicle Ophthalmic Solution
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Age-related Macular Degeneration
A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration
A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.
- Trial name
- NCT04151212
- Testing
- BAT5906 injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Bio-Thera Solutions
Macular Degeneration, Choroidal Neovascularization
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).
- Trial name
- NCT00100087
- Testing
- Ocular Brachytherapy
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Theragenics Corporation
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema, Myopic Choroidal Neovascularization
- Trial name
- NCT07550504
- Testing
- SB11 PFS
- Where
- 2 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Wet Macular Degeneration
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01243086)
- Testing
- Ranibizumab, OZURDEX
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Age-related Macular Degeneration
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
- Trial name
- NCT02214628
- Testing
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Ophthotech Corporation